Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 mai 2020 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Hold Virtual 2020 Annual Shareholder Meeting

SANTA MONICA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
12 mai 2020 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update

SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
28 avr. 2020 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Tuesday, May 12

SANTA MONICA, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
04 mars 2020 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
24 févr. 2020 16h01 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report Fourth Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, March 4

SANTA MONICA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
02 janv. 2020 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose

SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
12 déc. 2019 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
12 nov. 2019 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
05 nov. 2019 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on Tuesday, November 12

SANTA MONICA, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
10 oct. 2019 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Host a Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose

SANTA MONICA, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...

Page précédente

Page suivante